Danaher Co. (NYSE:DHR) Shares Sold by Brookstone Capital Management

Brookstone Capital Management lowered its holdings in Danaher Co. (NYSE:DHR) by 4.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,373 shares of the conglomerate’s stock after selling 413 shares during the period. Brookstone Capital Management’s holdings in Danaher were worth $2,091,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the fourth quarter valued at $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter valued at about $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher during the fourth quarter worth about $29,000. Rakuten Securities Inc. acquired a new position in shares of Danaher in the fourth quarter worth about $36,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher in the fourth quarter valued at about $41,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent analyst reports. Barclays upped their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and increased their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Bank of America increased their price target on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Finally, TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $269.29.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at approximately $28,352,350. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock valued at $37,536,717. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $250.03 on Friday. The company has a 50-day moving average price of $255.96 and a two-hundred day moving average price of $246.43. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $269.11. The stock has a market cap of $185.19 billion, a price-to-earnings ratio of 42.38, a price-to-earnings-growth ratio of 3.88 and a beta of 0.85. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same period last year, the firm earned $2.36 EPS. The firm’s revenue was down 2.6% compared to the same quarter last year. Analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.